FDA paused trials for experimental drugs more often in recent years

By Abigail Adcox

Published January 10, 2023 7:40pm ET

FDA paused trials for experimental drugs more often in recent years — President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File) | Andrew Harnik

The Food and Drug Administration has increasingly exercised its power to delay drug companies’ testing of experimental drugs in recent years, a possible byproduct of newer medical technologies that offer promise but may pose additional risks.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

FDA paused trials for experimental drugs more often in recent years

Recommended Stories

Why must US patients wait for drugs available in other countries?

Diabetes drugs in short supply as they grow in popularity as weight-loss tool

Mayo Clinic removes webpage citing hydroxychloroquine as COVID-19 remedy

Full midterm coverage.Deeper analysis.

Tag: